121 related articles for article (PubMed ID: 24269688)
1. Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.
Torii Y; Goto Y; Nakahira S; Kozaki S; Ginnaga A
Toxicon; 2014 Jan; 77():114-20. PubMed ID: 24269688
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.
Torii Y; Kiyota N; Sugimoto N; Mori Y; Goto Y; Harakawa T; Nakahira S; Kaji R; Kozaki S; Ginnaga A
Toxicon; 2011 Jan; 57(1):93-9. PubMed ID: 21029745
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.
Torii Y; Goto Y; Nakahira S; Kozaki S; Kaji R; Ginnaga A
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):524-8. PubMed ID: 25395371
[TBL] [Abstract][Full Text] [Related]
4. Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins.
Takeuchi T; Okuno T; Miyashiro A; Kohda T; Miyamoto R; Izumi Y; Kozaki S; Kaji R
Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822610
[TBL] [Abstract][Full Text] [Related]
5. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.
Torii Y; Akaike N; Harakawa T; Kato K; Sugimoto N; Goto Y; Nakahira S; Kohda T; Kozaki S; Kaji R; Ginnaga A
J Pharmacol Sci; 2011; 117(4):275-85. PubMed ID: 22123262
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and toxicity between botulinum toxin subtypes A1 and A2 in cynomolgus macaques.
Torii Y; Sasaki M; Shin MC; Akaike N; Kaji R
Toxicon; 2018 Oct; 153():114-119. PubMed ID: 30193802
[TBL] [Abstract][Full Text] [Related]
7. Clinical differences between A1 and A2 botulinum toxin subtypes.
Kaji R
Toxicon; 2015 Dec; 107(Pt A):85-8. PubMed ID: 26394198
[TBL] [Abstract][Full Text] [Related]
8. Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.
Torii Y; Shinmura M; Kohda T; Kozaki S; Takahashi M; Ginnaga A
Toxicon; 2013 Oct; 73():9-16. PubMed ID: 23834917
[TBL] [Abstract][Full Text] [Related]
9. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive effects of A1 and A2 type botulinum toxins on carrageenan-induced hyperalgesia in rat.
Shin MC; Yukihira T; Ito Y; Akaike N
Toxicon; 2013 Mar; 64():12-9. PubMed ID: 23270755
[TBL] [Abstract][Full Text] [Related]
11. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
Smith TJ; Lou J; Geren IN; Forsyth CM; Tsai R; Laporte SL; Tepp WH; Bradshaw M; Johnson EA; Smith LA; Marks JD
Infect Immun; 2005 Sep; 73(9):5450-7. PubMed ID: 16113261
[TBL] [Abstract][Full Text] [Related]
12. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
Shearer JD; Vassar ML; Swiderski W; Metcalfe K; Niemuth N; Henderson I
Vaccine; 2010 Oct; 28(45):7313-8. PubMed ID: 20816903
[TBL] [Abstract][Full Text] [Related]
13. Purification and characterization of a novel subtype a3 botulinum neurotoxin.
Tepp WH; Lin G; Johnson EA
Appl Environ Microbiol; 2012 May; 78(9):3108-13. PubMed ID: 22367089
[TBL] [Abstract][Full Text] [Related]
14. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.
Akaike N; Shin MC; Wakita M; Torii Y; Harakawa T; Ginnaga A; Kato K; Kaji R; Kozaki S
J Physiol; 2013 Feb; 591(4):1031-43. PubMed ID: 23109108
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.
Held DM; Shurtleff AC; Fields S; Green C; Fong J; Jones RG; Sesardic D; Buelow R; Burke RL
Clin Vaccine Immunol; 2010 Jun; 17(6):930-6. PubMed ID: 20410329
[TBL] [Abstract][Full Text] [Related]
17. A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.
Kaji R; Miyashiro A; Sato N; Furumoto T; Takeuchi T; Miyamoto R; Kohda T; Izumi Y; Kozaki S
Toxins (Basel); 2022 Oct; 14(11):. PubMed ID: 36355989
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library.
Yu R; Wang S; Yu YZ; Du WS; Yang F; Yu WY; Sun ZW
J Biomol Screen; 2009 Sep; 14(8):991-8. PubMed ID: 19726786
[TBL] [Abstract][Full Text] [Related]
19. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1.
Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY
J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529
[TBL] [Abstract][Full Text] [Related]
20. Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses.
Akaike N; Ito Y; Shin MC; Nonaka K; Torii Y; Harakawa T; Ginnaga A; Kozaki S; Kaji R
Toxicon; 2010 Dec; 56(8):1315-26. PubMed ID: 20674584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
